Cargando…

Enhanced humoral immunity in breast cancer patients with high serum concentration of anti‐HER2 autoantibody

Humoral immunity plays a substantial role in the suppression of breast cancer. We have revealed that a high serum concentration of anti‐HER2 autoantibody (HER2‐AAb) is associated with favorable outcomes in patients with invasive breast cancer. Thus, we aimed to clarify the association between high s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sato, Yasufumi, Shimoda, Masafumi, Sota, Yoshiaki, Miyake, Tomohiro, Tanei, Tomonori, Kagara, Naofumi, Naoi, Yasuto, Kim, Seung Jin, Noguchi, Shinzaburo, Shimazu, Kenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926031/ https://www.ncbi.nlm.nih.gov/pubmed/33506656 http://dx.doi.org/10.1002/cam4.3742

Ejemplares similares

Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
por: Hori, Ami, et al.
Publicado: (2019)

Highly sensitive detection of sentinel lymph node metastasis of breast cancer by digital PCR for RASSF1A methylation
por: Abe, Mizuho, et al.
Publicado: (2019)

A case of sternal osteomyelitis during treatment with everolimus for recurrent breast cancer
por: Abe, Kaori, et al.
Publicado: (2022)

Determining homologous recombination deficiency scores with whole exome sequencing and their association with responses to neoadjuvant chemotherapy in breast cancer
por: Kim, Seung Jin, et al.
Publicado: (2020)

Molecular Barcode Sequencing of the Whole Ligand Binding Domain of the ESR1 Gene in Cell-Free DNA from Patients with Metastatic Breast Cancer()
por: Masunaga, Nanae, et al.
Publicado: (2020)

Detection of ctDNA with Personalized Molecular Barcode NGS and Its Clinical Significance in Patients with Early Breast Cancer
por: Yoshinami, Tetsuhiro, et al.
Publicado: (2020)

Endocrine sensitivity of estrogen receptor‐positive breast cancer is negatively correlated with aspartate‐β‐hydroxylase expression
por: Shimoda, Masafumi, et al.
Publicado: (2017)

Promoter methylation of TRIM9 as a marker for detection of circulating tumor DNA in breast cancer patients
por: Mishima, Chieko, et al.
Publicado: (2015)

Identification of sentinel lymph nodes by contrast‐enhanced ultrasonography with Sonazoid in patients with breast cancer: a feasibility study in three hospitals
por: Shimazu, Kenzo, et al.
Publicado: (2017)

BRCA1 promoter methylation of normal breast epithelial cells as a possible precursor for BRCA1-methylated breast cancer
por: Otani, Yoko, et al.
Publicado: (2014)

Detection of Ultra-Rare ESR1 Mutations in Primary Breast Cancer Using LNA-Clamp ddPCR
por: Hashimoto, Yoko, et al.
Publicado: (2023)

Methylated DNA and high total DNA levels in the serum of patients with breast cancer following neoadjuvant chemotherapy are predictive of a poor prognosis
por: FUJITA, NORIKO, et al.
Publicado: (2014)

The multigene classifiers 95GC/42GC/155GC for precision medicine in ER‐positive HER2‐negative early breast cancer
por: Naoi, Yasuto, et al.
Publicado: (2021)

Evaluation of RASSF1A methylation in the lysate of sentinel lymph nodes for detecting breast cancer metastasis: A diagnostic accuracy study
por: Park, Sung Ae, et al.
Publicado: (2023)

Hypercalcemia affected in metastatic breast cancer patients without bone metastasis: report of three cases
por: Hashizume, Sakina, et al.
Publicado: (2022)

Emerging Technologies for Real‐Time Intraoperative Margin Assessment in Future Breast‐Conserving Surgery
por: Pradipta, Ambara R., et al.
Publicado: (2020)

ASO Author Reflections: Intraoperative Nomograms Based on One-Step Nucleic Acid Amplification
por: Shimazu, Kenzo, et al.
Publicado: (2018)

Validation of the prognosis of patients with ER‑positive, HER2‑negative and node‑negative invasive breast cancer classified as low risk by Curebest(™) 95GC Breast in a multi‑institutional registry study
por: Naoi, Yasuto, et al.
Publicado: (2023)

Intraoperative Nomograms, Based on One-Step Nucleic Acid Amplification, for Prediction of Non-sentinel Node Metastasis and Four or More Axillary Node Metastases in Breast Cancer Patients with Sentinel Node Metastasis
por: Shimazu, Kenzo, et al.
Publicado: (2018)

Radiogenomics of magnetic resonance imaging and a new multi-gene classifier for predicting recurrence prognosis in estrogen receptor-positive breast cancer: A preliminary study
por: Tokuda, Yukiko, et al.
Publicado: (2020)

Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib
por: Lian, Xiangyao, et al.
Publicado: (2020)

A small molecule inhibitor of HER3: a proof-of-concept study
por: Colomba, Audrey, et al.
Publicado: (2020)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
por: Watanabe, Satomi, et al.
Publicado: (2019)

Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer
por: Lander, Eric M, et al.
Publicado: (2022)

Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface
por: Claus, Jeroen, et al.
Publicado: (2018)

Correlation of ER, PR, and HER2 at the protein and mRNA levels in Asian patients with operable breast cancer
por: Chen, Chih-Jung, et al.
Publicado: (2022)

Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer
por: Kanematsu, Masako, et al.
Publicado: (2015)

Breast Cancer Diagnosis: Cascade Reaction in Human Live Tissue Allows Clinically Applicable Diagnosis of Breast Cancer Morphology (Adv. Sci. 2/2019)
por: Tanei, Tomonori, et al.
Publicado: (2019)

Cascade Reaction in Human Live Tissue Allows Clinically Applicable Diagnosis of Breast Cancer Morphology
por: Tanei, Tomonori, et al.
Publicado: (2018)

MGMT autoantibodies as a potential prediction of recurrence and treatment response biomarker for glioma patients
por: Wu, Haibin, et al.
Publicado: (2019)

HER2 as a target in invasive urothelial carcinoma
por: Bellmunt, Joaquim, et al.
Publicado: (2015)

HER2 status and disparities in luminal breast cancers
por: Holowatyj, Andreana N., et al.
Publicado: (2016)

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
por: Tripathy, Debu, et al.
Publicado: (2019)

Humor-Based Messaging in Testicular Cancer Awareness Campaigns: A Comparative Critical Review
por: Rovito, Michael J., et al.
Publicado: (2023)

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
por: Le Du, Fanny, et al.
Publicado: (2023)

Underuse of Anthracyclines in Women with HER-2(+) Advanced Breast Cancer
por: Montemurro, Filippo, et al.
Publicado: (2010)

Autoantibodies against tumor‐associated antigens combined with microRNAs in detecting esophageal squamous cell carcinoma
por: Sun, Guiying, et al.
Publicado: (2019)

ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells
por: Choi, Byung-Kwon, et al.
Publicado: (2012)

Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment
por: Ji, Chenchen, et al.
Publicado: (2023)

Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma
por: Qiu, Miao‐Zhen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ac1i6rv9ofhfbu6ro471o5df3p